Sanofi-Aventis Event - Search News

Sanofi, Escherichia coli and J&J

Sanofi Ends Trial for E. Coli Shot and Takes a $250 Million Hit

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an invasive form of the digestive pathogen E. coli.

Reuters on MSN · 1d

J&J, Sanofi stop E.coli vaccine trial due to low effectiveness

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the companies said on Thursday.

GlobalData on MSN · 1d

J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results

The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.

Seeking Alpha on MSN · 1d

Sanofi and J&J discontinue late stage trial of their experimental E.coli vaccine

Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The vaccine for extraintestinal pathogenic E.

pharmaphorum7d

Ex-Sanofi CEO backs first European biomanufacturing SPAC

Along with Le Fur – who was CEO at Sanofi predecessor Sanofi-Aventis in 2007 and 2008 – eureKING's backers include Michael Kloss, former head of Panasonic Healthcare, who will serve as CEO of ...

The Pharma Letter15d

Sanofi meets estimates for fourth-quarter profit

French pharma major Sanofi (Euronext: SAN) has met analyst estimates for its fourth-quarter 2024 profit and confirmed plans ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Sanofi, Escherichia coli and J&J

Trending now